Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.

Pharmacogenetics and genomics - 1 Aug 2007

Yoder Graber Andrea L, Ramírez Jacqueline, Innocenti Federico, Ratain Mark J

Abstract excerpt

OBJECTIVE: L-thyroxine (T4), the most widely used drug for hypothyroidism, undergoes glucuronidation by UDP-glucuronosyltransferases. Clinical evidence obtained after the administration of anticonvulsants suggest that glucuronidation may play an important role in T4 homeostasis in humans. The aims of this study were to determine the T4 glucuronidation ability of all commercially available human UGTs, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Flavonoids
Share to Glucuronates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronides

Share to Glucuronosyltransferase

Share to Microsomes, Liver

Share to Piperidines

Share to Thyroxine

Source

Identifiers

PMID: 17622938
DOI: 10.1097/FPC.0b013e3280121fe9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.PMID 17622938Read ↗

Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer.Semantic proximity Read ↗

UGT pharmacogenomicsSemantic proximity Read ↗

Influence of mutations associated with Gilbert and Crigler–Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substratesSemantic proximity Read ↗

Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.Semantic proximity Read ↗

UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.Semantic proximity Read ↗

Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family.Semantic proximity Read ↗

Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.Semantic proximity Read ↗

Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance.Semantic proximity Read ↗

The Impact of UGT1A1 Genetic Variability on Enzyme Expression in Liver Pathology.Semantic proximity Read ↗

UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation.Semantic proximity Read ↗

Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A).Semantic proximity Read ↗

Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.